Colleen Kusy

Stock Analyst at Baird

(1.82)
# 3,320
Out of 5,022 analysts
50
Total ratings
36.36%
Success rate
-8.13%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Colleen Kusy

Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17$24
Current: $11.85
Upside: +102.53%
Climb Bio
Aug 15, 2025
Initiates: Outperform
Price Target: $9
Current: $2.00
Upside: +350.00%
Apellis Pharmaceuticals
Jul 18, 2025
Maintains: Outperform
Price Target: $47$50
Current: $24.14
Upside: +107.13%
Nuvalent
Jun 25, 2025
Maintains: Outperform
Price Target: $105$112
Current: $89.75
Upside: +24.79%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40$52
Current: $20.66
Upside: +151.69%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4$6
Current: $4.05
Upside: +48.15%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37$41
Current: $21.00
Upside: +95.24%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4$6
Current: $1.73
Upside: +246.82%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50$65
Current: $18.92
Upside: +243.64%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $100$75
Current: $9.91
Upside: +656.81%
Reiterates: Outperform
Price Target: $27$25
Current: $13.91
Upside: +79.73%
Maintains: Outperform
Price Target: $255$210
Current: $5.62
Upside: +3,636.65%
Maintains: Outperform
Price Target: $30$34
Current: $2.14
Upside: +1,488.79%
Initiates: Outperform
Price Target: $230
Current: $2.31
Upside: +9,856.71%